MP34-13 NEOADJUVANT SORAFENIB, GEMCITABINE, AND CISPLATIN (SGC) FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIUBC): FINAL RESULTS AND TRANSLATIONAL FINDINGS OF AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY

Authors :: Salvatore Lo Vullo
Elena Togliardi
Tullio Torelli
Silvia Stagni
Giuseppina Calareso
Mario Catanzaro
Adele Busico
Andrea Necchi
Federica Perrone
Daniele Raggi
Maurizio Colecchia
Luigi Mariani
Patrizia Giannatempo
Davide Biasoni
Nicola Nicolai
Roberto Salvioni
Source :: Journal of Urology. 197
Publication Year :: 2017
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2017.

Subjects :: Sorafenib
Cisplatin
Oncology
medicine.medical_specialty
Bladder cancer
business.industry
Urology
Muscle invasive
Phases of clinical research
medicine.disease
Gemcitabine
Internal medicine
medicine
Open label
business
medicine.drug

Full Text Access

Tools